Seeking Alpha

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (ICCM) (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...
TMCnet

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system ...
Benzinga.com

Freezing Cancer With IceCure: ProSense Cryoablation System Receives FDA Marketing Authorization For Early-Stage Breast Cancer Treatment

IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...
Morningstar

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

CAESAREA, Israel, Sept. 15, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...
MarketWatch

IceCure's ProSense(R) Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

The MarketWatch News Department was not involved in the creation of this content. Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense(R) user at Kameda Medical ...
Nasdaq

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

CAESAREA, Israel, March 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...
Nasdaq

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

CAESAREA, Israel, March 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...
Essence

New FDA-Approved Breast Cancer Treatment Freezes Tumors Instead Of Removing Them

The ProSense® Cryoablation System could be a game changer for women over 70 with early-stage, low-risk breast cancer. For decades, breast cancer treatment has often meant surgery, which can be an ...

With aggressive breast cancer, 78-year-old couldn’t have surgery or chemotherapy: How did doctors save her

With aggressive breast cancer, 78-year-old couldn’t have surgery or chemotherapy: How did doctors save her ...
Kaleido Scope

UAB offers new minimally invasive treatment option for breast cancer patients

When cancer returned last year, it did so in a very different chapter of her life. This time, a rare stage IV sarcoma complicated her breast cancer. She now faced a difficult decision regarding ...
Seeking Alpha

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in ...

CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...